Myung In Pharmaceutical LTD. (KRX:317450)
South Korea · Delayed Price · Currency is KRW 56,900
+600 (1.07%)
At close: Apr 8, 2026
KRX:317450 Revenue
In the year 2025, Myung In Pharmaceutical LTD. had annual revenue of 287.25B KRW with 6.61% growth. Myung In Pharmaceutical LTD. had revenue of 72.09B in the quarter ending December 31, 2025, with 5.79% growth.
Revenue
287.25B
Revenue Growth
+6.61%
P/S Ratio
2.89
Revenue / Employee
857.48M
Employees
335
Market Cap
830.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 287.25B | 17.82B | 6.61% |
| Dec 31, 2024 | 269.43B | 27.10B | 11.18% |
| Dec 31, 2023 | 242.34B | 16.51B | 7.31% |
| Dec 31, 2022 | 225.83B | 16.58B | 7.92% |
| Dec 31, 2021 | 209.25B | 21.41B | 11.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 404.26B |
| GREEN CROSS WellBeing | 164.68B |
| DAE HWA Pharmaceutical | 143.06B |
| OPTUS Pharmaceutical | 87.16B |
| High Tech Pharm | 70.18B |
| Vivozon Pharmaceutical | 59.34B |
| HEM Pharma | 12.98B |
| CellBion | 1.95B |